Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alpha 1 antitrypsin modified process - Grifols

Next Previous
Drug Profile

Alpha 1 antitrypsin modified process - Grifols

Alternative Names: Alpha-1 MP - Grifols; Alpha-1 proteinase-inhibitor-modified process - Grifols; Alpha-1-antitrypsin IV - Grifols; Alpha-1-protease-inhibitor-modified process - Grifols; Alpha-antitrypsin modified process - Grifols; Alpha1-PI; Lynspad; Prolastin; Prolastin-C; Prolastin-C Liquid; Prolastina; Pulmolast; TAL 6004

Latest Information Update: 07 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Developer CSL Vifor; Grifols
  • Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Antiallergics; Antihyperglycaemics; Blood proteins; Ear disorder therapies; Enzymes; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action Immunomodulators; Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Alpha 1-antitrypsin deficiency
  • New Molecular Entity No

Highest Development Phases

  • Marketed Alpha 1-antitrypsin deficiency
  • Phase II COVID 2019 infections; Type 1 diabetes mellitus
  • Discontinued Chronic fatigue syndrome

Most Recent Events

  • 05 May 2026 Phase-III clinical trials in Alpha 1-antitrypsin deficiency in Denmark, Netherlands, Portugal, Sweden (SC) (NCT07555483) (CTIS2025-522792-29-00)
  • 05 May 2026 Grifols initiates enrolment in the phase III SWIFT-SC trial for Alpha 1-antitrypsin deficiency in Denmark, Sweden, Spain, and Portugal (IV) (NCT07555483) (CTIS2025-522792-29-00)
  • 02 Feb 2026 Grifols plans a phase III trial for Alpha 1-antitrypsin deficiency in USA, Denmark, Ireland, Netherlands, Poland, Portugal, Sweden (SC) (CTIS2025-522792-29-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top